This is evident in the frequent co-expression of myeloid markers and is the phenomenon familiar to every clinician of MLL-r B-ALL patients who relapse with apparent AML that is cytogenetically related or even identical to the initial lymphoid disease. Here, KMT2A is linked to acute lymphoblastic leukemia.